You just read:

Tolero Pharmaceuticals Advances Investigational Agent Alvocidib into Second Stage of Phase 2 Zella 201 Study in Patients with Relapsed Refractory MCL-1-Dependent AML

News provided by

Tolero Pharmaceuticals, Inc.

Jul 23, 2018, 08:00 ET